search
Back to results

ED Management of Severe Hyperglycemia: A Clinical Trial

Primary Purpose

Hyperglycemia, Diabetes Mellitus, Complications of Diabetes Mellitus

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Tight control: goal glucose 350 mg/dL or lower
Loose control: goal glucose 600 mg/dL or lower
Sponsored by
Hennepin Healthcare Research Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hyperglycemia

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Glucose of more than 400mg/dL but less than 600 mg/dL at any point in the ED
  • Working phone number and willing to discuss health status at 7-10 days via phone

Exclusion Criteria:

  • Plan for hospital admission
  • Already received insulin during the ED stay
  • Type 1 diabetes
  • Less than 18 years old
  • Non-English speaking
  • Altered mental status or encephalopathy (unable to provide informed consent)
  • DKA, as determined clinically by the treating physician, without a lab requirement.
  • Critically ill, as determined by the treating physician.
  • Unable to provide informed consent
  • Prisoners
  • Pregnant women

Sites / Locations

  • Hennepin County Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Tight control

Loose control

Arm Description

Patients in this arm will have a treatment glucose value at ED discharge of 350 mg/dL or lower.

Patients in this arm will have a treatment glucose value at ED discharge of 600 mg/dL or lower.

Outcomes

Primary Outcome Measures

ED Length of Stay
Time elapsed from when the patient is roomed until the time the MD places discharge order, by review of the Electronic Medical record by a blinded abstractor.

Secondary Outcome Measures

Iatrogenic hypoglycemia
Rate of iatrogenic hypoglycemia in both groups, defined as: glucose <60 or glucose less than 100 mg/dL and symptoms of hypoglycemia that resolved with food/drink, or any use of IV dextrose 50%, glucagon, or oral glucose tabs/gel
Return ED visit for hyperglycemia and hospital admission for any reason, excluding trauma
Composite outcome of rate of repeat ED visit for hyperglycemia or hospital admission for any reason, excluding trauma admission. ED visit for hyperglycemia defined as: chief complaint of hyperglycemia, chief complaint of polyuria, polydipsia, fatigue, blurry vision, or malaise and found to have blood glucose more than 250 mg/dL, primary ED diagnosis of hyperglycemia, or ED or hospital diagnosis of DKA or hyperosmolar syndrome.
Return ED visit for any reason
Each patient will be assessed via chart review and telephone follow up to see if they visited an ED for any reason during the 7 day time frame. Rates of ED visits for any reason at 7 days will be compared between the two treatment arms.

Full Information

First Posted
June 17, 2015
Last Updated
March 20, 2018
Sponsor
Hennepin Healthcare Research Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT02478190
Brief Title
ED Management of Severe Hyperglycemia: A Clinical Trial
Official Title
ED Management of Severe Hyperglycemia: An Open-Label Randomized Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
March 2018
Overall Recruitment Status
Completed
Study Start Date
June 2015 (Actual)
Primary Completion Date
December 2017 (Actual)
Study Completion Date
December 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Hennepin Healthcare Research Institute

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Emergency Department (ED) patients with severe hyperglycemia will be randomized to two treatment goals: discharge glucose less than 600 mg/dL or less than 350 mg/dL. Randomization is stratified by whether the chief complaint is "High Blood Sugar" in the electronic medical record or other.
Detailed Description
It is common practice to provide insulin and/or intravenous (IV) fluids to lower glucose levels prior to discharge in patients that present with hyperglycemia. There is, however, no data supporting this practice. A recent retrospective observational cohort study (HSR# 12-3497) of 567 ED patients with severe hyperglycemia demonstrated no association between discharge glucose levels and short-term adverse outcomes at 7 days (return ED visits, diabetic ketoacidosis (DKA), hospitalization, and death). There were no other short-term adverse outcomes associated with the degree of glycemic control. Less than 1% of patients developed DKA at 7 days. No patients died. As this was a retrospective study, the conclusions that can be drawn are limited by the lack of randomization and control; it is necessary to conduct a randomized controlled trial to quantify how much time is expended caring for these patients, and gather safety data. This is important because much time and money is focused on glucose reduction, which may not change short-term outcomes. Furthermore, in retrospective analysis approximately 1.5% of patients receiving therapy for hyperglycemia developed iatrogenic hypoglycemia during the ED stay. To detect a difference in length of stay by 60 minutes (Standard deviation is 100 minutes) with an p=0.05 and b=0.8, enrollment of 45 patients per group will be required, with a total enrollment of 90 patients. Enrollment will stop when 45 patients in each group have been contacted in follow-up. This study will only include patients who are discharged from the ED. Patients who are enrolled and then eventually admitted to the hospital will be tabulated but excluded from the length of stay analysis. Statistical analysis will be completed for the primary outcome with a Mann-Whitney U test, assuming the data will not be normally distributed. Secondary outcomes will be compared with chi-squared testing. A secondary regression model will be formed, based on covariates that could influence ED length of stay, such as amount of diagnostic testing completed.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hyperglycemia, Diabetes Mellitus, Complications of Diabetes Mellitus, Diabetes-Related Complications, Diabetes Mellitus, Type 2

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
110 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Tight control
Arm Type
Experimental
Arm Description
Patients in this arm will have a treatment glucose value at ED discharge of 350 mg/dL or lower.
Arm Title
Loose control
Arm Type
Experimental
Arm Description
Patients in this arm will have a treatment glucose value at ED discharge of 600 mg/dL or lower.
Intervention Type
Other
Intervention Name(s)
Tight control: goal glucose 350 mg/dL or lower
Intervention Description
Goal glucose at discharge will be 350 mg/dL or less.
Intervention Type
Other
Intervention Name(s)
Loose control: goal glucose 600 mg/dL or lower
Intervention Description
Goal glucose at discharge will be 600 mg/dL or less.
Primary Outcome Measure Information:
Title
ED Length of Stay
Description
Time elapsed from when the patient is roomed until the time the MD places discharge order, by review of the Electronic Medical record by a blinded abstractor.
Time Frame
This outcome measure is defined as the amount of time elapsed between when the patient is roomed, and when a discharge order is placed, during a single ED encounter, which is generally less than 4 hours.
Secondary Outcome Measure Information:
Title
Iatrogenic hypoglycemia
Description
Rate of iatrogenic hypoglycemia in both groups, defined as: glucose <60 or glucose less than 100 mg/dL and symptoms of hypoglycemia that resolved with food/drink, or any use of IV dextrose 50%, glucagon, or oral glucose tabs/gel
Time Frame
The patient will be followed during a single ED encounter, which is generally less than 4 hours.
Title
Return ED visit for hyperglycemia and hospital admission for any reason, excluding trauma
Description
Composite outcome of rate of repeat ED visit for hyperglycemia or hospital admission for any reason, excluding trauma admission. ED visit for hyperglycemia defined as: chief complaint of hyperglycemia, chief complaint of polyuria, polydipsia, fatigue, blurry vision, or malaise and found to have blood glucose more than 250 mg/dL, primary ED diagnosis of hyperglycemia, or ED or hospital diagnosis of DKA or hyperosmolar syndrome.
Time Frame
7 days
Title
Return ED visit for any reason
Description
Each patient will be assessed via chart review and telephone follow up to see if they visited an ED for any reason during the 7 day time frame. Rates of ED visits for any reason at 7 days will be compared between the two treatment arms.
Time Frame
7 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Glucose of more than 400mg/dL but less than 600 mg/dL at any point in the ED Working phone number and willing to discuss health status at 7-10 days via phone Exclusion Criteria: Plan for hospital admission Already received insulin during the ED stay Type 1 diabetes Less than 18 years old Non-English speaking Altered mental status or encephalopathy (unable to provide informed consent) DKA, as determined clinically by the treating physician, without a lab requirement. Critically ill, as determined by the treating physician. Unable to provide informed consent Prisoners Pregnant women
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Brian Driver, MD
Organizational Affiliation
HCMC
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hennepin County Medical Center
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55415
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
30316635
Citation
Driver BE, Klein LR, Cole JB, Prekker ME, Fagerstrom ET, Miner JR. Comparison of two glycemic discharge goals in ED patients with hyperglycemia, a randomized trial. Am J Emerg Med. 2019 Jul;37(7):1295-1300. doi: 10.1016/j.ajem.2018.09.053. Epub 2018 Oct 5.
Results Reference
derived

Learn more about this trial

ED Management of Severe Hyperglycemia: A Clinical Trial

We'll reach out to this number within 24 hrs